目的 討論替吉奧聯(lián)合奧沙利鉑治療晚期胃癌患者的臨床療效。方法 選取2016年3—2017年3月青海大學(xué)附屬醫(yī)院收治的晚期胃癌患者80例，隨機(jī)分為對照組和治療組，每組各40例。對照組靜脈滴注注射用奧沙利鉑，90 mg/m²溶于5%葡萄糖溶液500 mL，持續(xù)3～4 h，1次/14 d。治療組在對照組的基礎(chǔ)上口服替吉奧膠囊，2粒/次，2次/d。兩組患者持續(xù)治療28 d。觀察兩組患者臨床療效，比較治療前后兩組患者生存質(zhì)量及血清腫瘤壞死因子-α（TNF-α）、白介素-6（IL-6）和IL-10水平。結(jié)果 治療后，對照組客觀緩解率和疾病控制率分別為52.5%、72.5%，均分別顯著低于治療組的77.5%、92.5%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，治療組軀體功能、情緒功能、認(rèn)知功能和社會功能評分顯著高于對照組，食欲下降、便秘和睡眠障礙癥狀評分顯著低于對照組，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療后兩組上述評分均顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者血清TNF-α、IL-6、IL-10水平均顯著低于治療前，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者上述血清因子水平顯著低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 替吉奧聯(lián)合奧沙利鉑治療晚期胃癌臨床療效較好，能改善患者的生存質(zhì)量，有效降低患者血清TNF-α、IL-6、IL-10的表達(dá)，具有一定的臨床應(yīng)用價值。

Objective To discuss the curative effect of tegafur, gimeracil and oteracil potassium combined with oxaliplatin in treatment of advanced gastric cancer. Methods Patients (80 cases) with advanced gastric cancer in Affiliated Hospital of Qinghai University from March 2016 to March 2017 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were iv administered with Oxaliplatin for injection, 90 mg/m² added into 5% glucose solution 500 mL, and maintained for 3-4 h, once every 14 d. Patients in the treatment group were po administered with Tegafur, Gimeracil and Oteracil Potassium Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 28 d. After treatment, the clinical efficacy was evaluated, and the quality of life, serum TNF-α, IL-6, and IL-10 levels in two groups before and after treatment were compared. Results After treatment, the ORR and CBR in the control group were 52.5% and 72.5%, which were significantly lower than 77.5% and 92.5% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, physical function, emotional function, cognitive function, and social function scores in two groups were significantly increased, and the symptom of loss of appetite, constipation, and somnipathy scores significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And those scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the TNF-α, IL-6 and IL-10 levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these serum factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Tegafur, gimeracil and oteracil potassium combined with oxaliplatin can effectively reduce serum TNF-α, IL-6 and IL-10 levels and improve quality of life in treatment of advanced gastric cancer.